[go: up one dir, main page]

WO2008132138A9 - AMINOPYRIMIDINE DERIVATIVES DISUBSTITUTED IN 4 AND 6 - Google Patents

AMINOPYRIMIDINE DERIVATIVES DISUBSTITUTED IN 4 AND 6 Download PDF

Info

Publication number
WO2008132138A9
WO2008132138A9 PCT/EP2008/055015 EP2008055015W WO2008132138A9 WO 2008132138 A9 WO2008132138 A9 WO 2008132138A9 EP 2008055015 W EP2008055015 W EP 2008055015W WO 2008132138 A9 WO2008132138 A9 WO 2008132138A9
Authority
WO
WIPO (PCT)
Prior art keywords
derivatives
methylenesulfonamide
methylenesulfone
acceptable salts
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/055015
Other languages
French (fr)
Other versions
WO2008132138A1 (en
Inventor
Axel Choidas
Bert Klebl
Gerhard Mueller
Wilfried Schwab
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ingenium Pharmaceuticals GmbH
Original Assignee
Ingenium Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ingenium Pharmaceuticals GmbH filed Critical Ingenium Pharmaceuticals GmbH
Publication of WO2008132138A1 publication Critical patent/WO2008132138A1/en
Publication of WO2008132138A9 publication Critical patent/WO2008132138A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention a trait à des dérivés méthylènesulfone et méthylènesulfonamide d'aminopyrimidines disubstituées en 4 et en 6 de formule générale (II) et/ou à leurs sels pharmaceutiquement acceptables. L''invention concerne également l'utilisation de ces dérivés en tant qu'agents pharmaceutiquement actifs, en particulier dans la prophylaxie et/ou le traitement de maladies à prolifération cellulaire, l'inflammation, l'hypertrophie cardiaque et les maladies infectieuses, en particulier les infections virales comme le VIH. Par ailleurs, cette invention se concentre sur une composition pharmaceutique contenant au moins l'un des dérivés méthylènesulfone ou méthylènesulfonamide d'aminopyrimidines disubstituées en 4 et en 6 et/ou leurs sels pharmaceutiquement acceptables.The present invention relates to methylenesulfone and methylenesulfonamide derivatives of 4- and 6-disubstituted aminopyrimidines of the general formula (II) and / or their pharmaceutically acceptable salts. The invention also relates to the use of these derivatives as pharmaceutically active agents, particularly in the prophylaxis and / or treatment of cell-proliferative diseases, inflammation, cardiac hypertrophy and infectious diseases, in particular especially viral infections such as HIV. Furthermore, this invention concentrates on a pharmaceutical composition containing at least one of the methylenesulfone or methylenesulfonamide derivatives of 4-and 6-disubstituted aminopyrimidines and / or their pharmaceutically acceptable salts.

PCT/EP2008/055015 2007-04-25 2008-04-24 Derivatives of 4,6-disubstituted aminopyrimidines Ceased WO2008132138A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07106951 2007-04-25
EP07106951.2 2007-04-25

Publications (2)

Publication Number Publication Date
WO2008132138A1 WO2008132138A1 (en) 2008-11-06
WO2008132138A9 true WO2008132138A9 (en) 2008-12-31

Family

ID=38515868

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/055015 Ceased WO2008132138A1 (en) 2007-04-25 2008-04-24 Derivatives of 4,6-disubstituted aminopyrimidines

Country Status (1)

Country Link
WO (1) WO2008132138A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU0900798D0 (en) 2009-12-21 2010-03-01 Vichem Chemie Kutato Kft 4-phenylamino-pyrimidine derivatives having protein kinase inhibitor activity
WO2012066065A1 (en) * 2010-11-17 2012-05-24 Novartis Ag Phenyl-heteroaryl amine compounds and their uses
CA2826464C (en) * 2011-03-02 2020-07-28 Lead Discovery Center Gmbh Pharmaceutically active disubstituted triazine derivatives
EP2681193B1 (en) 2011-03-02 2016-01-06 Lead Discovery Center GmbH Pharmaceutically active disubstituted pyridine derivatives
TWI555737B (en) 2011-05-24 2016-11-01 拜耳知識產權公司 4-aryl-N-phenyl-1,3,5-triazabenzene-2-amine containing a sulfonium imine group
EP2561867A1 (en) 2011-08-22 2013-02-27 Lead Discovery Center GmbH CDK9 inhibitors in the treatment of midline carcinoma
EP2562265A1 (en) 2011-08-22 2013-02-27 Lead Discovery Center GmbH Susceptibility to selective CDK9 inhibitors
ES2595222T3 (en) 2012-10-18 2016-12-28 Bayer Pharma Aktiengesellschaft 5-Fluoro-N- (pyridin-2-yl) pyridin-2-amine derivatives containing a sulfone group
HK1215246A1 (en) * 2012-10-18 2016-08-19 Bayer Pharma Aktiengesellschaft N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group
TW201418243A (en) * 2012-11-15 2014-05-16 Bayer Pharma AG N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfoximine group
DK2928878T3 (en) 2012-11-15 2016-12-19 Bayer Pharma AG 5-Fluoro-N- (pyridin-2-yl) pyridine-2-amine derivatives containing a SULFOXIMINGRUPPE
EP2941428A1 (en) * 2013-01-07 2015-11-11 Vichem Chemie Kutató KFT 4-pyrimidinylamino-benzenesulfonamide derivatives and their use for the inhibition of polo-like kinase 1 (plk1) for the treatment of cancer and their use for the treatment of bacterial infections
EP2769722A1 (en) * 2013-02-22 2014-08-27 Ruprecht-Karls-Universität Heidelberg Compounds for use in inhibiting HIV capsid assembly
JP6371385B2 (en) 2013-07-04 2018-08-08 バイエル ファーマ アクチエンゲゼルシャフト Sulfoximine substituted 5-fluoro-N- (pyridin-2-yl) pyridin-2-amine derivatives and their use as CDK9 kinase inhibitors
CA2942119A1 (en) 2014-03-13 2015-09-17 Bayer Pharma Aktiengesellschaft 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
JP6503372B2 (en) 2014-04-01 2019-04-17 バイエル ファーマ アクチエンゲゼルシャフト Di-substituted 5-fluoro pyrimidine derivative containing sulfone diimine group
AU2015243585B2 (en) 2014-04-11 2019-08-01 Bayer Pharma Aktiengesellschaft Novel macrocyclic compounds
EP3207037B1 (en) 2014-10-16 2019-01-23 Bayer Pharma Aktiengesellschaft Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfone group
CN107001341B (en) 2014-10-16 2020-08-07 拜耳医药股份有限公司 Fluorinated benzofuranyl-pyrimidine derivatives containing sulfonimide groups
LT3313838T (en) 2015-06-29 2019-06-10 Astrazeneca Ab Polycyclic amide derivatives as cdk9 inhibitors
EP3601236A1 (en) 2017-03-28 2020-02-05 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
US11254690B2 (en) 2017-03-28 2022-02-22 Bayer Pharma Aktiengesellschaft PTEFb inhibiting macrocyclic compounds
US20210101881A1 (en) * 2018-02-12 2021-04-08 Ancureall Pharmaceutical (Shanghai) Co., Ltd. Pyrimidine compound, preparation method thereof and medical use thereof
CA3090843A1 (en) 2018-02-13 2019-08-22 Bayer Aktiengesellschaft Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-{4-[(s-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large b-cell lymphoma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7419984B2 (en) * 2002-10-17 2008-09-02 Cell Therapeutics, Inc. Pyrimidines and uses thereof
WO2005026129A1 (en) * 2003-09-15 2005-03-24 Gpc Biotech Ag Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
EP1901747A2 (en) * 2005-05-25 2008-03-26 Ingenium Pharmaceuticals AG Pyrimidine-based cdk inhibitors for treating pain

Also Published As

Publication number Publication date
WO2008132138A1 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
WO2008132138A9 (en) AMINOPYRIMIDINE DERIVATIVES DISUBSTITUTED IN 4 AND 6
MA27647A1 (en) CCR5 ANTAGONISTS USEFUL AS THERAPEUTIC AGENTS
MA31021B1 (en) DERIVATIVES OF ISOQUINOLEINE AND ISOQUINOLEINONE SUBSTITUTED AS RHO-KINASE INHIBITORS
MA33606B1 (en) PYRIMIDINE DERIVATIVES AS TYROSINE KINASE 2 PROTEIN INHIBITORS
MA31022B1 (en) SUBSTITUTED ISOQUINOLINE AND ISOQUINOLEINONE DERIVATIVES
MA29170B1 (en) PURINIC DERIVATIVES AS A2A RECEPTOR AGONISTS
MA29240B1 (en) INDOLE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS
MA31076B1 (en) Isocinoline derivatives and cycloquine substituted isocinoline.
MA29713B1 (en) DERIVATIVES OF TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE
MA31598B1 (en) ANTIVIRAL COMPOUNDS, COMPOSITIONS AND METHODS OF USE
MA30333B1 (en) AMINOTETRAHYDROPYRANES USEFUL AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV FOR THE TREATMENT OR PREVENTION OF DIABETES.
BRPI0508876A (en) piperazine and substituted piperidine antiviral agents
MA30717B1 (en) PYRIDIN-3-YLE DERIVATIVES AS IMMUNOMODULATORS
MA30718B1 (en) PYRIDIN-4-YLE DERIVATIVES AS IMMUNOMODULATORS.
MA45598B1 (en) 24-hydroxy steroles substituted in position 11 for the treatment of diseases linked to the nmda receptor
TNSN07022A1 (en) PYRIDINE DERIVATIVES
MA31024B1 (en) NOVEL SUBSTITUTED ISOQUINOLINE AND ISOQUINOLEINONE DERIVATIVES
EP1624874A4 (en) 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IN THE TREATMENT OR PREVENTION OF DIABETES
MA27009A1 (en) PYRAZOLE DERIVATIVES FOR THE TREATMENT OF HIV INFECTION
ATE405269T1 (en) CYCLOHEXYL COMPOUNDS AS CCR5 ANTAGONISTS
MA33768B1 (en) Trichlorethylene
BR0317572A (en) Benzoxazine and its derivatives as inhibitors of pi3ks
MA30806B1 (en) ENANTIOMERICALLY PURE PHOSPHOINDOLS USEFUL AS HIV INHIBITORS
MA54653B1 (en) Modulators of the cxcr7 piperidine receptor
MA29692B1 (en) XANTHINE DERIVATIVES AS SELECTIVE AGONISTS OF HM74A

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08736548

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08736548

Country of ref document: EP

Kind code of ref document: A1